Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Sigma-Tau
Pomezia, Latium/Lazio, Italy
- Ownership
- Private
- Employees
- ~400
- Development stage
- Other
01
Overview
Sigma-Tau was a major Italian pharmaceutical group focused on research and development of therapies for rare diseases and other serious conditions. It developed both proprietary small molecules and biologics. Its portfolio included marketed drugs such as Abelcet®, Carnitor®, Cystaran®, Matulane®, VSL#3® probiotic formulations, as well as clinical-stage assets like istaroxime for heart failure and tenatumomab for cancer. The company had a strong focus on rare/orphan indications through its US subsidiary. In August 2017 it merged with Alfa Wassermann to form Alfasigma S.p.A., ceasing independent operations but continuing its legacy within the new entity.
- Therapeutic areas
- GastroenterologyCardiovascularMetabolic DisordersOphthalmologyImmunologyHematologyOtherOncologyRare DiseasesInfectious Diseases
- Modalities
- small moleculesmonoclonal antibodiesbiologicsprobioticsnutraceuticals
- Industry
- Biotech
02
Partnerships
Debiopharm Group for istaroxime R&D/commercialization agreementcollaborations with Chinese partners on anti-malarial drug development from traditional medicine sources.
Beyond the preview
Go deeper on Sigma-Tau.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sigma-Tau.